These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 29103187)
1. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA. Ivanova JI; Saverno KR; Sung J; Duh MS; Zhao C; Cai S; Vekeman F; Peevyhouse A; Dhawan R; Fuchs CS Med Oncol; 2017 Nov; 34(12):193. PubMed ID: 29103187 [TBL] [Abstract][Full Text] [Related]
2. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer. Chung C; Pherwani N Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964 [TBL] [Abstract][Full Text] [Related]
3. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268 [TBL] [Abstract][Full Text] [Related]
4. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence. Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671 [TBL] [Abstract][Full Text] [Related]
5. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Van Cutsem E; Joulain F; Hoff PM; Mitchell E; Ruff P; Lakomý R; Prausová J; Moiseyenko VM; van Hazel G; Cunningham D; Arnold D; Schmoll HJ; Ten Tije AJ; McKendrick J; Kröning H; Humblet Y; Grávalos C; Le-Guennec S; Andria M; Dochy E; Vishwanath RL; Macarulla T; Tabernero J Target Oncol; 2016 Jun; 11(3):383-400. PubMed ID: 26706237 [TBL] [Abstract][Full Text] [Related]
6. Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer. Perkins SL; Cole SW Ann Pharmacother; 2014 Jan; 48(1):93-8. PubMed ID: 24259608 [TBL] [Abstract][Full Text] [Related]
7. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. Ruff P; Van Cutsem E; Lakomy R; Prausova J; van Hazel GA; Moiseyenko VM; Soussan-Lazard K; Dochy E; Magherini E; Macarulla T; Papamichael D J Geriatr Oncol; 2018 Jan; 9(1):32-39. PubMed ID: 28807738 [TBL] [Abstract][Full Text] [Related]
8. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147 [TBL] [Abstract][Full Text] [Related]
9. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. Strickler JH; Rushing CN; Niedzwiecki D; McLeod A; Altomare I; Uronis HE; Hsu SD; Zafar SY; Morse MA; Chang DZ; Wells JL; Blackwell KL; Marcom PK; Arrowood C; Bolch E; Haley S; Rangwala FA; Hatch AJ; Nixon AB; Hurwitz HI BMC Cancer; 2019 Nov; 19(1):1032. PubMed ID: 31675952 [TBL] [Abstract][Full Text] [Related]
10. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. Chau I; Joulain F; Iqbal SU; Bridgewater J BMC Cancer; 2014 Aug; 14():605. PubMed ID: 25142418 [TBL] [Abstract][Full Text] [Related]
11. Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. Pastorino A; Di Bartolomeo M; Maiello E; Iaffaioli V; Ciuffreda L; Fasola G; Di Costanzo F; Frassineti GL; Marchetti P; Antoniotti C; Leone F; Zaniboni A; Aprile G; Zilocchi C; Sobrero A; Bordonaro R Clin Colorectal Cancer; 2018 Sep; 17(3):e457-e470. PubMed ID: 29605592 [TBL] [Abstract][Full Text] [Related]
12. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. Joulain F; Proskorovsky I; Allegra C; Tabernero J; Hoyle M; Iqbal SU; Van Cutsem E Br J Cancer; 2013 Oct; 109(7):1735-43. PubMed ID: 24045663 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer. Chong DQ; Manalo M; Imperial M; Teo P; Yong G; Ng M; Tan IB; Choo SP; Chua C Asia Pac J Clin Oncol; 2016 Sep; 12(3):275-83. PubMed ID: 27075236 [TBL] [Abstract][Full Text] [Related]
14. Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program. Salgado Fernández M; Pérez Hoyos MT; Díaz de Corcuera I; Vidal Arbués A; García de la Torre M Expert Opin Drug Saf; 2015 Aug; 14(8):1171-9. PubMed ID: 26076885 [TBL] [Abstract][Full Text] [Related]
15. Aflibercept: A Review in Metastatic Colorectal Cancer. Syed YY; McKeage K Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis. Fernández Montes A; López López C; Argilés Martínez G; Páez López D; López Muñoz AM; García Paredes B; Gutiérrez Abad D; Castañón López C; Jiménez Fonseca P; Gallego Plazas J; López Doldán MC; Martínez de Castro E; Sánchez Cánovas M; Tobeña Puyal M; Llorente Ayala B; Juez Martel I; López Flores M; Carmona-Bayonas A Oncologist; 2019 Aug; 24(8):e687-e695. PubMed ID: 31147489 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain. Feliu J; Díez de Corcuera I; Manzano JL; Valladares-Ayerbes M; Alcaide J; García García T; Vera R; Sastre J Clin Transl Oncol; 2017 Apr; 19(4):498-507. PubMed ID: 27718155 [TBL] [Abstract][Full Text] [Related]
18. Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR? Vera R; Mata E; González E; Juez I; Alonso V; Iranzo P; Martínez NP; López C; Cabrera JM; Safont MJ; Ruiz-Casado A; Salgado M; González B; Escudero P; Rivera F; Pericay C Int J Colorectal Dis; 2020 Apr; 35(4):739-746. PubMed ID: 32062727 [TBL] [Abstract][Full Text] [Related]
19. Targeted therapy for metastatic colorectal cancer: role of aflibercept. Mitchell EP Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896 [TBL] [Abstract][Full Text] [Related]
20. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Tang PA; Cohen SJ; Kollmannsberger C; Bjarnason G; Virik K; MacKenzie MJ; Lourenco L; Wang L; Chen A; Moore MJ Clin Cancer Res; 2012 Nov; 18(21):6023-31. PubMed ID: 22977191 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]